论文部分内容阅读
目的:观察阿霉素持续静脉输注联合国产长春瑞滨(盖诺NVB)治疗晚期乳腺癌的疗效及毒副反应,探讨治疗方式改变在化疗中的价值。方法:32例晚期乳腺癌患者,用NA方案:NVB 25 mg/m2ivgtt d1,8、ADM 50 mg/m2civ 96h d1~4。每28天为一周期,至少2周期后评价疗效。观察疗效及毒副反应。结果:32例患者均随访。总共用药170周期,平均5.3周期。CR 5例,PR 18例,RR(CR+PR)71.9%。初治、复治有效率分别为73.3%、70.6%,二者间无显著性差异(P>0.05)。中位缓解期8.2个月。主要毒副反应为白细胞降低,发生率100%(32/32),32例中Ⅲ~Ⅳ度下降15例(46.9%);恶心、呕吐23例(71.9%),Ⅲ~Ⅳ度4例(12.5%);均发生脱发,Ⅲ~Ⅳ度5例(15.6%);口腔炎16例(50.0%),Ⅲ~Ⅳ度4例(12.5%);静脉炎2例(6.2%),均为Ⅰ度;心脏毒性发生3例(9.4%),为Ⅰ、Ⅱ度不等。无治疗相关性死亡。结论:阿霉素持续静脉输注与盖诺联合治疗晚期转移性乳腺癌疗效明确,毒副反应可以耐受,远期疗效值得进一步研究。
OBJECTIVE: To observe the efficacy and side effects of continuous intravenous infusion of doxorubicin in combination with vinorelbine (NVB) in the treatment of advanced breast cancer and to explore the value of treatment modality in chemotherapy. Methods: Thirty-two patients with advanced breast cancer were treated with NA regimen: NVB 25 mg / m2ivgtt d1,8 and ADM 50 mg / m2 civ 96h d1-4. Every 28 days for a period, at least 2 weeks after the evaluation of efficacy. To observe the efficacy and toxicity. Results: 32 patients were followed up. A total of 170 cycles of medication, an average of 5.3 cycles. CR 5 cases, PR 18 cases, RR (CR + PR) 71.9%. The rates of initial treatment and retreatment were 73.3% and 70.6% respectively, with no significant difference (P> 0.05). The median remission period of 8.2 months. The main toxicities were leukopenia, the incidence was 100% (32/32), 32 cases decreased from Ⅲ to Ⅳ in 15 cases (46.9%), nausea and vomiting in 23 cases (71.9%) and Ⅲ ~ Ⅳ degrees in 4 cases 12.5%); all had hair loss, grade Ⅲ ~ Ⅳ in 5 cases (15.6%); stomatitis in 16 cases (50.0%), Ⅲ ~ Ⅳ degrees in 4 cases Ⅰ degree; cardiotoxicity occurred in 3 cases (9.4%), Ⅰ, Ⅱ degrees. No treatment-related deaths. Conclusion: Continuous doxorubicin infusion combined with Ginorol has a clear curative effect in treating advanced metastatic breast cancer. Toxicity and side effects can be tolerated. Long-term efficacy is worthy of further study.